home / stock / oncs / oncs news

ONCS News and Press, OncoSec Medical Incorporated From 06/04/20

Stock Information
Company Name: OncoSec Medical Incorporated
Stock Symbol: ONCS
Market: NASDAQ
Menu
ONCS ONCS Quote ONCS Short ONCS News ONCS Articles ONCS Message Board
Get ONCS Alerts

News, Short Squeeze, Breakout and More Instantly...
ONCS - OncoSec to Present at Virtual Summer Investor Summit

PENNINGTON, N.J. and SAN DIEGO , June 4, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor , President and Chief Executive Offic...
ONCS - 47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

NEW YORK, NY / ACCESSWIRE / June 3, 2020 / The Virtual Summer Summit will take place on June 9 th -12 th , connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below along with webcasting links to view pre...

ONCS - OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO(TM) and Its Electroporation Gene Delivery System

PENNINGTON, N.J. and SAN DIEGO , May 27, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced Notices of Allowance for three new patent applications coverin...

ONCS - OncoSec to Present Two Late-Breaking Pre-Clinical Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II

PENNINGTON, N.J. and SAN DIEGO , May 21, 2020 /PRNewswire/ --  OncoSec Medical Incorporated (the "Company" or "OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that it will present new pre-clinical data demonstrating th...
ONCS - OncoSec Partners with the Melanoma Research Foundation to Host Live Panel Discussion during Melanoma Awareness Month

PENNINGTON, N.J. and SAN DIEGO , May 14, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, announced today that its partnering with the Melanoma Research Foundation (MRF) to raise awareness ab...

ONCS - Study planned for OncoSec COVID-19 vaccine candidate

Investigators at Providence Cancer Institute are on board with a Phase 1 clinical trial evaluating OncoSec Medical's (NASDAQ: ONCS ) CORVax12 COVID-19 vaccine candidate. They hope for FDA sign-off by month-end. More news on: OncoSec Medical Incorporated, Healthcare stocks news, Stocks on...

ONCS - OncoSec's TAVO(TM) Receives ATMP Certification from European Medicines Agency to Support Marketing Authorization Application in Metastatic Melanoma

PENNINGTON, N.J. and SAN DIEGO , May 13, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (Nasdaq:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced the European Medicines Agency (EMA) issued an advanced therapy...
ONCS - OncoSec's TAVO(TM) in Combination with KEYTRUDA® Demonstrated 41% Overall Response Rate and 36% Complete Response in a Late-Stage Metastatic Melanoma Study Featured in 'Clinical Cancer Research'

SAN DIEGO and PENNINGTON, N.J. , May 6, 2020 /PRNewswire/ --  Oncosec Medical Incorporated (the "Company" or "Oncosec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced published data in Clinical Cancer Research , linked here ,...

ONCS - OncoSec Presents Pre-Clinical Data from Its Visceral Lesion Applicator (VLA) and APOLLO Feasibility Study Demonstrating TAVO(TM) Can Be Safely Delivered and Electroporated in Liver at the Online Society of Interventional Radiology Annual Meeting

SAN DIEGO and PENNINGTON, N.J. , April 21, 2020 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (Nasdaq: ONCS) , a company developing late-stage intratumoral cancer immunotherapies, today announced pre-clinical data from a feasibility study of its visceral lesion applicator (V...

ONCS - OncoSec Appoints Renowned Oncologist and Immunologist, Herbert Kim Lyerly, M.D., Duke University, to its Board of Directors

SAN DIEGO and PENNINGTON, N.J. , April 20, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (Nasdaq:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced the appointment of Herbert Kim Lyerly , M.D., George Barth ...
Previous 10 Next 10